SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense discussion and trending upwards, fueled by reports of substantial institutional buying and notable options activity. The community is bullish, highlighting strong technical indicators and increasing volume as signs of an impending breakout. This surge in interest is also attributed to a broader positive shift in housing market sentiment and a rotation into small-cap technology stocks.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW, or Crow with Knife, is trending due to its prominent multi-chain presence, actively bridging across networks like Solana, Cronos, and Ethereum via Layerzero technology. The community is generating significant buzz around its fully decentralized, organic growth, and deflationary burn mechanism, positioning it as a compelling contender within the meme coin sector.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amidst sharp market volatility, primarily driven by recent downgrades from major financial institutions, which many in the community perceive as a manipulative tactic by competitors to acquire shares at a discount. This intense trading activity is prompting discussions of a strategic buying opportunity for long-term holders, anticipating strong upcoming earnings and potential S&P 500 inclusion, despite frustration over what's seen as repeated institutional tactics.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively trending due to renewed geopolitical focus on Greenland's strategic rare earth deposits, highlighted by U.S. administration comments and the appointment of a special envoy. The community is widely discussing the potential for government investment or partnership in CRML's Tanbreez project, viewing it as vital for Western supply chain independence and eagerly anticipating upcoming feasibility study results.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is generating significant buzz following its recent substantial debt reduction and the strategic acquisition of Ask Sage, firmly positioning the company in secure generative AI for defense and government sectors. The community is actively discussing the imminent potential for major government contract wins, often drawing comparisons to early Palantir, despite some persistent chatter about potential share dilution. Many investors foresee a breakout into double-digit prices, driven by its strengthened financial position and perceived critical role in national security applications.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following its inclusion in the S&P MidCap 400, which has generated significant investor buzz around anticipated institutional buying and increased liquidity. The community is highly optimistic, discussing the company's pivotal role in agentic AI orchestration and its potential for substantial growth as enterprises accelerate autonomous automation adoption.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amid an intense rally in memory and storage stocks, driven by soaring demand from AI infrastructure buildouts and rising prices for essential components. The community is actively debating if its rapid appreciation reflects a legitimate "memory supercycle" or an "overpriced bubble," with many expressing FOMO while others anticipate a pullback. This strong movement is widely seen as a reflection of the broader sector's response to unprecedented AI-driven data center needs.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing significant investor interest driven by anticipation of an upcoming Congressional hearing on nuclear energy and a crucial DOE announcement regarding surplus plutonium allocation. The community is actively discussing the potential for a short squeeze and institutional accumulation, viewing these catalysts as pivotal for the company's role in powering AI data centers and advancing the 'new nuclear era'.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience (RGC) is trending due to an exceptionally high borrow rate and extremely low share availability, fueling community speculation about an imminent short squeeze. Traders are actively discussing the potential for a "GME 2.0" type parabolic run, referencing the stock's history of massive price movements. The conversation centers on shorts being trapped and key price level breaks that could trigger significant upward momentum.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending following the announcement of highly positive Phase 3 clinical trial results for its oral TYK2 inhibitor in moderate-to-severe plaque psoriasis, showcasing strong skin clearance and a favorable safety profile. While many celebrate the drug's "best in class" potential, the community is actively debating the likelihood of an imminent stock offering that could impact short-term valuation and create volatility amidst heavy trading action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.66% and -94.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates

Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates

Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Equity

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.


Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.

VXRT
Vaxart Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VXRT News

VXRTVaxart Inc